share_log

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83

HC Wainwright & Co. 维持对Apellis Pharmaceuticals的买入评级,将目标价下调至83美元
Benzinga ·  08/02 17:21  · 评级/大行评级

HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $92 to $83.

HC Wainwright & Co. 分析师Douglas Tsao 维持apellis pharmaceuticals(纳斯达克: APLS)的买入评级,将目标价从92美元降至83美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发